• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » King’s College London, RCT establish new company

King’s College London, RCT establish new company

October 19, 2015
CenterWatch Staff

A new company, Femtogenix, has been formed by King’s College London and Research Corporation Technologies (RCT) of Tucson, Ariz., with RCT also providing Series A funding for the venture. The new company is based on the work of David Thurston, professor of drug discovery, and his colleagues Dr. Miraz Rahman and Dr. Paul Jackson at King’s College London.

Dr. Chris Keightley has been named the CEO. The company will operate in the Britannia House research laboratories of King’s College in Trinity Street, London, within the Institute of Pharmaceutical Sciences (IPS).

The main aim of Femtogenix is to develop a new generation of very potent molecules—known as “payloads”—that can be attached to targeting systems and then used as a form of highly specific chemotherapy to kill cancer cells with greatly reduced side effects.

The targeting systems are usually (although not always) based on antibodies, in which case the final agents are known as Antibody Drug Conjugates (ADCs). After the successful commercialization of Kadcyla (Genentech/Roche) and Adcetris (Seattle Genetics) in the past few years, ADCs now constitute a large proportion of the novel anticancer therapies currently undergoing clinical trials worldwide. There is a real need for new payload molecules due to the limitations of existing ones, and consequently there is intense interest by pharmaceutical companies in acquiring the most effective molecules to attach to their delivery systems.

Keightley said, “We plan to expand and develop our platform of novel payload molecules and make these available to biopharma companies through partnering and licensing arrangements. The early indications are that these new molecules will address the needs of those wanting to make the next generation of Antibody Drug Conjugates.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing